

OTCQB: DFCO

Q2 2024 Earnings Presentation



Company Overview

Dalrada drives innovation that positively impacts people, businesses, and the planet. The company owns and operates a global group of health care, clean energy, precision manufacturing, and technology companies that identify, address, and deliver solutions to economic, environmental, and efficiency problems facing the public, government, and private sectors.

Genefic

Genefic delivers an exciting core of frontline health products and services that meet the world's demands of today and tomorrow. Dedicated to creating improved health outcomes through redesigned systems and reimagined patient care, **Genefic** offers total health solutions through distinctive offerings.



Dalrada Climate Technology (DCT) is revolutionizing the global clean energy industry through state-of-the-art products—like heat pumps—that help build a sustainable energy future. DCT's unique solutions reduce energy consumption and minimize carbon footprints, increase operational efficiencies, and lower energy costs for clients around the world.







Dalrada Precision Manufacturing (DPM) meets today's critical manufacturing needs and provides highquality parts and components solutions. Additionally, DPM improves time-tomarket capabilities and solves the world's biggest manufacturing and supply chain challenges as a specialized service provider committed to delivering improved efficiencies.

Dalrada Technologies is a proud creator of digital engineering that eclipses standard capabilities. Through nextgeneration B2B and B2C digital products and services, **Dalrada Technologies** connects the world through cutting-edge software programming, modernized applications, and robust IT products specifically tailored for the digital age.







.


MM Start

Genefic

Total: \$11.1 million

Fiscal Year 2024 **Revenue Breakdown**









Q2 2024 **Financial Highlights**



TOTAL COST OF REVENUE: \$4.1 million



TOTAL CONSOLIDATED SALES, GENERAL, AND **ADMINISTRATIVE COSTS:**

\$6.2 million



TOTAL CONSOLIDATED LOSS OF OPERATIONS:

\$4.2 million



LOSS PER SHARE (EPS): \$.06

2.5

4.5

4

3.5

3

1.5

2 —


1

0.5

0



TOTAL CONSOLIDATED REVENUE:





Dalrada Climate Technology Heat Pump (DCT ONE Series)

State-of-the-art climate technology that combines unrivaled energy efficiency with an extremely low environmental impact.

Internationally-recognized heat pump solution that supports global Net Zero initiatives. ✓ U.S. General Services Administration & Department of Energy-identified "green building technology."

The **Dalrada's commercial heat pump** is the **only** CO2–based heat pump that delivers simultaneous heating and cooling without combustion or the burning of fossil fuels. It's the perfect replacement for outdated and inefficient water heaters, steam boilers, chillers, and cooling towers.

Why DCT ONE Series?

- Long-Term Cost Savings: lower energy bills through reduced consumption.
- Increased Energy Efficiency: advanced technology and climate-agnostic design.
- Comfort and Convenience: better temperature control with real-time reporting.
- Less Environmental Impact: lower emissions and reduced carbon footprint.
- Rebates and Incentives: increased eligibility for reduced overall costs.

Signed, Sealed, (almost) Delivered:

Dalrada Climate Technology has secured a backlog of international contracts worth approximately **\$900 million**:

- ✓ **2,300**-heat pump contract with JBS Consulting, a Paris-based distributor (5-year contract length).
- ✓ 4,500-heat pump contract with Crown Glory Holding, a Morocco-based global distributor (7-year contract length).

Climate Technology

DECARBONIZING SOLUTIONS Cost-Effective Heating & Cooling

DCT ONE Series by the Numbers:

- \checkmark Up to 7 times more efficient than traditional systems
- ✓ Up to 75% reduced energy consumption
- \checkmark Up to 60– 80% energy savings



			-
	=	-	
ē			

Genefic Specialty Pharmacy

Enhanced patient support through prescriptions, medical education, advocacy, and increased transparency.

Genefic Specialty Pharmacy offers a pharmacy experience like no other: a nationallyrecognized and certified local pharmacy with a global reach, delivering modern services for a busy world. As a full-service provider, they are redefining personalized healthcare in a way that's educational and transparent for patients and medical staff alike.

In addition to basic pharmacy services, **Genefic Specialty Pharmacy** provides enhanced prescription management, comprehensive and ongoing wellness education, and complete medical assistance for a variety of health conditions.

Expanded Service Offerings:

- Medical condition education
- Diabetes care
- Durable medical equipment (DME)
- Health screenings
- Home delivery
- Immunizations
- Medication therapy
- Wellness classes

Core Values:

- Advocate on behalf of patients
- Facilitate patient education
- Improve patient lives daily
- Create transparency between patients and staff
- Employ highly-trained, ethical pharmacists and technicians



Redefining the modern pharmaceutical experience.



Dalrada Precision Manufacturing

Meeting the critical quality of today's advanced machining and manufacturing needs for global industries.

Dalrada Precision Manufacturing responds to consumer challenges with in-house design, engineering, and distribution through an efficient supply chain and improved time-to-market capabilities.

The subsidiary exceeds the standard of quality of today's advanced products in a variety of industries, including semiconductors, automotive, aviation, biotechnology, pharmaceuticals, and clean energy.

- OEM & custom precision parts
- Clean energy technology & machinery
- Semiconductor & microchip technology
- Industrial-strength cleaners & degreasers

Key Components

- Design and development
- In-house solutions
- Global supply chain
- Engineering excellence



A total end-to-end manufacturing solution delivering high-quality components.



Dalrada Technologies

Next-generation digital products and services that connect the world through integrated technological solutions.

Dalrada creates a suite of B2B and B2C solutions through a global development team of technology and digital engineering experts.

With hyper-personalized, web 3.0 solutions that eclipse standard digital engineering capabilities, **Dalrada** offers advanced software programming, modernized applications, and robust IT products and services specifically tailored for the digital age.

Future-Facing Science

- Software engineering and testing
- Application modernization
- Advanced digital ecosystems
- Digital twinning and machine learning
- Artificial intelligence
- Metaverse and virtual reality

Modern Results

- Better user experiences
- Increased data security
- Improved accuracy
- Safer digital experiences
- Inclusive environments
- Efficient communications

Digital engineering that transcends traditional capabilities.



Metrics – Q2 vs. Q1 2024

Revenue Increase \$1.1 million increase of 21.1%

Q2 2024 OVER Q1 2024 HIGHLIGHTS:

GROSS MARGIN


+106.2%


SALES, GENERAL, AND ADMINISTRATIVE EXPENSES * +5.6%


OPERATING LOSS *


-19.1%


* Excludes stock-based compensation of \$1,018,827 and \$1,109,642 for the three months ended December 31, 2023 and September 30, 2023, respectively.














Dalrada Revenue (Fiscal 2021-2024)








Unaudited Consolidated Statements of Operations

	Three Months EndedSix Months EndedDecember 31,December 31,		d					
		2023		2022	2	2023		2022
Revenues	\$	5,859,240		,603,878		,980,866		776,127
Revenues - related party		218,522		649,242	,	,114,976	,	734,760
Total revenues	-	6,077,762	5	,253,120	11,	,095,842	9,	510,887
Cost of revenues		4,076,002	2	,955,132	8,	,123,224	5,	311,460
Gross profit		2,001,760	2	,297,988	2,	,972,618	4,	199,427
Operating expenses:								
Selling, general and administrative (includes stock-based compensation of \$1,018,827 and \$901,721 for the three months and	l							
\$2,128,469 and \$1,369,238 for the six months ended 2023 and								
2022, respectively)		6,227,434	7.	,080,077	12,	,270,088	11,	937,694
Total operating expenses		6,227,434		,080,077		,270,088		937,694
Loss from operations		(4,225,674)	(4	,782,089)	(9,	,297,470)	(7,	738,267)
Other income (expense):								
Interest expense		(213,960)	(1	,220,603)	((327,153)	(1,	892,730)
Interest income		20,884		22,826		40,127		41,895
Other income		(1,023,079)	((444,699)	((688,699)	(106,622)
Gain on expiration of accrued tax liability		-	2	,037,712		-	2,	090,978
Gain (loss) on foreign exchange		1,649		(95,312)		(5,121)		(47,595)
Total other income (expense), net		(1,214,506)		299,924	((980,846)		85,926
Loss before taxes		(5,440,180)	(4	,482,165)	(10,	,278,316)	(7,	652,341)
Income taxes	_	-		-		-		-
Net loss		(5,440,180)	(4	,482,165)	(10,	,278,316)	(7,	652,341)
Other comprehensive loss								
Foreign currency translation		(39,026)		(34,129)		46,182		29,633
Comprehensive loss	\$	(5,479,206)	\$ (4	,516,294)	\$(10,	,232,134)	\$ (7,	622,708)
Net income (loss) attributable to noncontrolling interests		(33,982)		(69,147)		(55,876)		378,466
Net loss attributable to Dalrada Financial Corporation stockholders	\$	(5,406,198)	\$ (4	,413,018)	\$(10,	,222,440)	\$ (8,	030,807)
Net loss per common share to Dalrada stockholders - basic	\$	(0.06)	\$	(0.05)	\$	(0.11)	\$	(0.10)
•	♪ \$		ъ \$		ֆ \$		ֆ \$	· · · · ·
Net loss per common share to Dalrada stockholders - diluted	Φ	(0.06)	Φ	(0.05)	Φ	(0.11)	Φ	(0.10)
Weighted average common shares outstanding — basic		89,962,164	84	,437,801	89,	,120,328	80,	721,783
Weighted average common shares outstanding — diluted		89,962,164		,437,801		,120,328		,721,783
				,,		,- , 		1,700



Unaudited Consolidated Balance Sheet

	December 31, 2023	June 30, 2023		
Assets	(Unaudited)			
Current assets:				
Cash and cash equivalents	\$ 598,438	\$ 812,806		
Accounts receivable, net	5,488,915	4,453,104		
Accounts receivable, net - related parties	928,648	752,348		
Other receivables	1,240,009	376,604		
Inventories	2,569,843	2,078,692		
Prepaid expenses and other current assets	668,877	1,343,491		
Total current assets	11,494,730	9,817,045		
Long-term receivables	20,141	41,722		
Long-term receivables - related parties	1,155,479	1,173,893		
Property and equipment, net	1,623,011	1,476,082		
Goodwill	3,803,147	3,803,147		
Intangible assets, net	3,654,823	3,858,086		
Right-of-use asset, net	2,714,198	2,771,854		
Right-of-use asset, net - related party	1,960,494	2,227,286		
Total assets	\$ 26,426,023	\$ 25,169,115		
10141 455015	\$ 20,420,025	\$ 25,109,115		
Liabilities and Stockholders' Equity				
Current liabilities:				
Accounts payable	\$ 5,554,117	\$ 5,178,897		
Accrued liabilities	\$ 5,554,117 920,159	1,084,008		
		547,949		
Accounts payable and accrued liabilities – related parties Deferred revenue	5,029,683	,		
	938,823	1,337,259		
Notes payable, current portion	439,562	439,562		
Notes payable, current portion – related parties	-	251,605		
Right-of-use liability	757,569	660,394		
Right-of-use liability - related party	536,265	519,791		
Total current liabilities	14,176,178	10,019,465		
Long-term payables	33,893	48,888		
Notes payable	2,414,936	1,011,395		
Notes payable – related parties	4,834,971	1,648,478		
Contingent consideration	4,402,394	4,285,389		
Right-of-use liability	2,027,911	2,160,834		
Right-of-use liability - related party	1,467,407	1,741,830		
Total liabilities	29,357,690	20,916,279		
Commitments and contingencies (Note 14)				
Stockholders' equity:				
Stockholder's equity: Series I preferred stock, \$0.01 par value, 100,000 shares authorized, 35,108 shares issued and				
	251	251		
outstanding as of December 31, 2023 and June 30, 2023, respectively	351	351		
Series H preferred stock, \$0.01 par value, 15,002 shares authorized, issued and	1 50	1.50		
outstanding og at Dagamban (1 101) and bing (1) 1001 and signal (1)	150	150		
outstanding as of December 31, 2023 and June 30, 2023, respectively		100		
Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding	100	100		
Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively	100	100		
Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and				
 Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively 	100 50	50		
 Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 	50	50		
 Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively 	50 471,443	50 443,478		
 Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively Common stock to be issued 	50 471,443 128,925	50 443,478 192,925		
 Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively Common stock to be issued Additional paid-in capital 	50 471,443	50 443,478		
 Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively Common stock to be issued 	50 471,443 128,925	50 443,478 192,925		
 Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively Common stock to be issued Additional paid-in capital 	50 471,443 128,925 148,335,488	50 443,478 192,925 145,251,822		
 Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively Common stock to be issued Additional paid-in capital Accumulated deficit 	50 471,443 128,925 148,335,488 (151,951,449)	50 443,478 192,925 145,251,822 (141,729,009)		
 Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively Common stock to be issued Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss 	50 471,443 128,925 148,335,488 (151,951,449) (4,666)	50 443,478 192,925 145,251,822 (141,729,009) (50,848)		
 Series G preferred stock, \$0.01 par value, 100,000 shares authorized, 10,002 shares issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Series F preferred stock, \$0.01 par value, 5,000 shares authorized, issued and outstanding as of both December 31, 2023 and June 30, 2023, respectively Common stock, \$0.005 par value, 1,000,000,000 shares authorized, 90,392,109 and 88,699,139 shares issued and outstanding at December 31, 2023 and June 30, 2023, respectively Common stock to be issued Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Total Dalrada Financial Corp's stockholders' equity 	50 471,443 128,925 148,335,488 (151,951,449) (4,666) (3,019,608)	50 443,478 192,925 145,251,822 (141,729,009) (50,848) 4,109,019		











Transformative Innovations.



Publicly traded on the OTC:QB under the symbol "\$**DFCO**"



in y f

San Diego Office 600 La Terraza Blvd. Escondido, CA 92025

Phone: 858.283.1253 Email: DFCOinquiries@dalrada.com Website: Dalrada.com





